Clover Health Investments, Corp. (CLOV): A Bull Case Theory

We came across a bullish thesis on Clover Health Investments, Corp. on topsecretstocks’s Substack. In this article, we will summarize the bulls’ thesis on CLOV. Clover Health Investments, Corp.'s share was trading at $2.5400 as of January 13th. CLOV’s  forward P/E was 109.89 respectively according to Yahoo Finance.

Clover Health has long divided Wall Street, oscillating between optimism and doubt as it seeks to disrupt the highly complex and inefficient U.S. Medicare Advantage market. Positioned as a technology-driven insurer, Clover’s strategy centers on using data and artificial intelligence to deliver lower costs while improving care quality, challenging traditional insurance models that struggle with rising medical expenses.

At the core of this approach is Counterpart Health, Clover’s unified clinical technology platform built to help clinicians manage quality outcomes, risk adjustment, and total cost of care within Medicare Advantage. Marketed as software designed specifically for physicians, Counterpart Health highlights its real-world success within Clover’s own insurance operations, where measurable financial and clinical improvements have already been demonstrated.

The data shows that members whose primary care physicians actively use the Counterpart Assistant experience a roughly 1,500 basis point improvement in medical cost ratios compared with those who do not, underscoring the platform’s ability to materially reduce costs. Importantly, this advantage compounds over time, with the MCR performance gap expanding from approximately 8% in the first year to nearly 20% by the fourth year as cohorts mature. Quality metrics reinforce this impact, as the platform helped Clover achieve the top HEDIS score nationwide for a PPO Medicare Advantage plan operating with independent, non-employed physicians and no capitation structure, an outcome that highlights both scalability and clinical effectiveness.

Adoption trends further validate the platform’s potential beyond Clover’s internal use. Counterpart Health has seen live clinician usage grow more than 450% year over year, with the majority of that expansion occurring in just the last three months, signaling accelerating momentum. Physician feedback supports this growth, emphasizing usability and clinical relevance that reflect software built by doctors for doctors. While Clover Health remains underappreciated by the broader market, the combination of improving economics, proven quality outcomes, and rapid platform adoption suggests patient investors may ultimately be rewarded.

Previously we covered a bullish thesis on UnitedHealth Group Incorporated by FluentInQuality in May 2025, which highlighted the company’s scale advantages, Optum-driven vertical integration, and leadership alignment. The company’s stock price has appreciated by approximately 13.19% since our coverage. This is because Medicare Advantage scale and integration advantages continued to support performance. Topsecretstocks shares a similar view, emphasizing technology-led cost reduction within Medicare Advantage.

Clover Health Investments, Corp. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 12 hedge fund portfolios held CLOV at the end of the third quarter which was 17 in the previous quarter. While we acknowledge the potential of CLOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.